EXPEDITION

Live / Registered — Registered (as of 11 Aug 2026)

What this means for you

Registered since 11 Aug 2026. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 11 Aug 2032: the §8 declaration of use).

Record

Serial number
98978174
Registration number
8394632
Mark type
Word mark
Filed
04 Oct 2024
Published for opposition
16 Sept 2025
Registered
11 Aug 2026
Next maintenance filing
§8 declaration of use, due by 11 Aug 2032 (grace period to 11 Feb 2033)
Attorney of record
Christina M. Licursi

Goods and services

  • Class 005 — Pharmaceuticals: Pharmaceuticals for the treatment, prevention, mitigation, management, or diagnosis of cancer, and viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system-related, autoimmune, genetic, rare, hematological, musculoskeletal, rheumatological, renal, nutritional, otolaryngological, pediatric, developmental, age-related, and pain-related diseases and disorders; therapeutics, namely, therapeutic agents for the treatment, prevention, mitigation, management, or diagnosis of cancer, and viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system-related, autoimmune, genetic, rare, hematological, musculoskeletal, rheumatological, renal, nutritional, otolaryngological, pediatric, developmental, age-related, and pain-related diseases and disorders; protein-based and small molecule therapeutics, namely, therapeutic agents for the treatment, prevention, mitigation, management, or diagnosis of cancer, and viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system-related, autoimmune, genetic, rare, hematological, musculoskeletal, rheumatological, renal, nutritional, otolaryngological, pediatric, developmental, age-related, and pain-related diseases and disorders; protein-based and small molecule pharmaceuticals for the treatment, prevention, mitigation, management, or diagnosis of cancer, and viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system-related, autoimmune, genetic, rare, hematological, musculoskeletal, rheumatological, renal, nutritional, otolaryngological, pediatric, developmental, age-related, and pain-related diseases and disorders
  • Class 042 — Scientific and technological services: Scientific research, namely, research and analysis services for the design and characterization of chemical therapeutic products; research services in the fields of proteomic analysis; proteomic analysis for scientific and research purposes; medical and scientific research in the field of proteomics; research and development in the field of proteomics; medical research, namely, compiling data for research purposes in the field of proteomics

Owner

Prosecution history

  • 11 Aug 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
  • 11 Aug 2026 — REGISTERED-PRINCIPAL REGISTER
  • 21 Jul 2026 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
  • 21 Jul 2026 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
  • 16 Jul 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
  • 16 Jul 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
  • 16 Jul 2026 — ASSIGNED TO LIE
  • 14 Jul 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
  • 10 Jun 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
  • 10 Jun 2026 — NON-FINAL ACTION E-MAILED
  • 10 Jun 2026 — SU - NON-FINAL ACTION - WRITTEN
  • 27 May 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 26 May 2026 — STATEMENT OF USE PROCESSING COMPLETE
  • 11 Dec 2025 — USE AMENDMENT FILED
  • 26 May 2026 — SOU EXTENSION 2 GRANTED

View this trademark record on Rightsy